The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Argos Therapeutics Inc. | Common | 040221103 | 2,377 | 13,242,279 | SH | DFND | 1 | 0 | 13,242,279 | 0 | |
| Argos Therapeutics Inc. | Common | 040221103 | 919 | 5,120,604 | SH | Call | DFND | 1 | 0 | 5,120,604 | 0 |
| Proteon Therapeutics Inc. | Common | 74371L109 | 3,336 | 1,667,907 | SH | DFND | 1 | 0 | 1,667,907 | 0 | |
| Protagonist Therapeutics, Inc. | Common | 74366E102 | 17,357 | 982,270 | SH | DFND | 1 | 0 | 982,270 | 0 | |
| Jounce Therapeutics, Inc. | Common | 481116101 | 10,315 | 662,063 | SH | DFND | 1 | 0 | 662,063 | 0 | |